ABSTRACT

This invention relates to compounds of formula (I) or (II)

wherein, in either formula, independently;

 R^1 and R^2 are the same or are different and are $C_{1:8}$ alkyl, $C_{2:8}$ alkylene, $C_{3:8}$ cycloalkyl, aryl, heteroaryl, heterocycloalkyl, $C_{3:6}$ cycloalkylaryl, or heterocycloaryl; wherein said alkyl, alkylene, cycloalkyl, aryl, heteroaryl, heterocyclyl, cycloalkylaryl, or heterocycloaryl are unsubstituted or substituted by one or more groups selected from the group consisting of halogen, $C_{1:8}$ alkyl, $C_{1:8}$ alkoxy, $C_{1:8}$ thioalkoxy, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, C_{F_3} , SCF₃, NHC(O)_nR³, S(O)_mR³, S(O)₂NR³R⁶, C(S)NR³R⁶, CONR³R⁶, C(O)_nR⁵;

n is 0, 1 or 2:

m is 0, 1 or 2;

R⁵ is hydrogen, alkyl, aryl, alkylaryl, heterocycloalkyl, or heteroaryl and is unsubstituted or substituted by one or more groups selected from the group consisting of alkyl, C₁₋₈alkoxy, aryl, heteroaryl, halogen, NO₂, CN, N₃, SCF₃, and CF₃;

R⁶ is hydrogen, alkyl, aryl, alkylaryl, heterocycloalkyl, or heteroaryl and is unsubstituted or substituted by one or more groups selected from the group consisting of alkyl, C_{1.8}alkoxy, aryl, heteroaryl, halogen, NO₂, CN, N₃, SCF₃, and CF₃, or when R¹ and/or R² contains S(O)₂NR²R⁶, CONR³R⁶, or C(S)NR³R⁶, then R³R⁶ together with the nitrogen may form a heterocyclic ring; or

a pharmaceutically acceptable salt or solvate thereof.